Vimarsana
Biggest News Aggregation in the World

Springwork Annual Report News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Springwork Annual Report. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Springwork Annual Report Today - Breaking & Trending Today

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American ... - Vimarsana News

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American ...

– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors - Vimarsana News

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in...

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates - Vimarsana News

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

– Reported OGSIVEO™ net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to...

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RA - Vimarsana News

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RA

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of B...

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in P - Vimarsana News

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in P

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifiraf...